Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells

Molecular Therapy Methods and Clinical Development

Volumn 2, Issue , 2015, Pages 15043-

  Sioud, Mouldy ^a   Westby, Phuong ^a   Olsen, Julie Kristine E ^a   Mobergslien, Anne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD16 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GAMMA INTERFERON; GE FC FUSION PROTEIN; GE MY FC FUSION PROTEIN; HYBRID PROTEIN; INTERLEUKIN 2; LACTATE DEHYDROGENASE; LTV FC FUSION PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MY FC FUSION PROTEIN; UNCLASSIFIED DRUG; WN FC FUSION PROTEIN; GROWTH FACTOR RECEPTOR; HER 1 PROTEIN; IMMUNOGLOBULIN G1; PEPTIDE FC FUSION PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DEGRANULATION; EC50; HEK293 CELL LINE; HT-29 CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; LUNG FIBROBLAST; MELANOMA CELL LINE; MESENCHYMAL STEM CELL; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN ENGINEERING; PROTEIN EXPRESSION; TRANSIENT EXPRESSION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CELL ACTIVATION; COLON CANCER; DNA SEQUENCE; EMBRYO; IN VITRO STUDY; LUNG CANCER; OVARY CANCER; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN PURIFICATION; SKIN CANCER; WESTERN BLOTTING;

EID: 84996969018     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.43     Document Type: Article

References (53)

1. 1 Paci, A, Veal, G, Bardin, C, Levêque, D, Widmer, N, Beijnen, J, et al. Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics. Eur J Cancer 50 (2014), 2010–2019.
2. 2 Mack, PC, Gandara, DR, Lara, PN Jr, Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the ‘common arm’ approach. Expert Rev Anticancer Ther 12 (2012), 1591–1596.
3. 3 Bhutia, SK, Maiti, TK, Targeting tumors with peptides from natural sources. Trends Biotechnol 26 (2008), 210–217.
4. 4 Shadidi, M, Sioud, M, Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 6 (2003), 363–371.
5. 5 Beck, A, Wurch, T, Bailly, C, Corvaia, N, Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10 (2010), 345–352.
6. 6 Seidel, UJ, Schlegel, P, Lang, P, Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol, 4, 2013, 76.
7. 7 Vivier, E, Tomasello, E, Baratin, M, Walzer, T, Ugolini, S, Functions of natural killer cells. Nat Immunol 9 (2008), 503–510.
8. 8 Nimmerjahn, F, Ravetch, JV, Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8 (2008), 34–47.
9. 9 Niwa, R, Sakurada, M, Kobayashi, Y, Uehara, A, Matsushima, K, Ueda, R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11 (2005), 2327–2336.
10. 10 Mössner, E, Brünker, P, Moser, S, Püntener, U, Schmidt, C, Herter, S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115 (2010), 4393–4402.
11. 11 Smith, GP, Petrenko, VA, Phage display. Chem Rev 97 (1997), 391–410.
12. 12 Kehoe, JW, Kay, BK, Filamentous phage display in the new millennium. Chem Rev 105 (2005), 4056–4072.
13. 13 Pasqualini, R, Ruoslahti, E, Organ targeting in vivo using phage display peptide libraries. Nature 380 (1996), 364–366.
14. 14 Shadidi, M, Sioud, M, Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J 17 (2003), 256–258.
15. 15 Oyama, T, Sykes, KF, Samli, KN, Minna, JD, Johnston, SA, Brown, KC, Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett 202 (2003), 219–230.
16. 16 Lo, A, Lin, CT, Wu, HC, Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 7 (2008), 579–589.
17. 17 Urbanelli, L, Ronchini, C, Fontana, L, Menard, S, Orlandi, R, Monaci, P, Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage. J Mol Biol 313 (2001), 965–976.
18. 18 McGuire, MJ, Samli, KN, Chang, YC, Brown, KC, Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp Hematol 34 (2006), 443–452.
19. 19 Wu, X, Huang, H, Wang, C, Lin, S, Huang, Y, Wang, Y, et al. Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation. Oncotarget 4 (2013), 1819–1828.
20. 20 Wang, XF, Birringer, M, Dong, LF, Veprek, P, Low, P, Swettenham, E, et al. A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. Cancer Res 67 (2007), 3337–3344.
21. 21 Florczak, A, Mackiewicz, A, Dams-Kozlowska, H, Functionalized spider silk spheres as drug carriers for targeted cancer therapy. Biomacromolecules 15 (2014), 2971–2981.
22. 22 Moreno, M, Zurita, E, Giralt, E, Delivering wasp venom for cancer therapy. J Control Release 182 (2014), 13–21.
23. 23 Gong, C, Pan, D, Qiu, F, Sun, P, Zhang, YH, Selective DNA delivery to tumor cells using an oligoarginine-LTVSPWY peptide. PLoS One, 9, 2014, e110632.
24. 24 Luo, H, Yang, J, Jin, H, Huang, C, Fu, J, Yang, F, et al. Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo. FASEB J 25 (2011), 1865–1873.
25. 25 Pastorino, F, Brignole, C, Di Paolo, D, Nico, B, Pezzolo, A, Marimpietri, D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 66 (2006), 10073–10082.
26. 26 Zhan, C, Gu, B, Xie, C, Li, J, Liu, Y, Lu, W, Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 143 (2010), 136–142.
27. 27 Guan, H, McGuire, MJ, Li, S, Brown, KC, Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers. Bioconjug Chem 19 (2008), 1813–1821.
28. 28 Wang, T, D'Souza, GG, Bedi, D, Fagbohun, OA, Potturi, LP, Papahadjopoulos-Sternberg, B, et al. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond) 5 (2010), 563–574.
29. 29 Arap, W, Haedicke, W, Bernasconi, M, Kain, R, Rajotte, D, Krajewski, S, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 99 (2002), 1527–1531.
30. 30 Wu, B, Sun, YN, Pharmacokinetics of peptide-Fc fusion proteins. J Pharm Sci 103 (2014), 53–64.
31. 31 Shimamoto, G, Gegg, C, Boone, T, Quéva, C, Peptibodies: a flexible alternative format to antibodies. MAbs 4 (2012), 586–591.
32. 32 Huang, C, Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 20 (2009), 692–699.
33. 33 Qin, H, Lerman, B, Sakamaki, I, Wei, G, Cha, SC, Rao, SS, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 20 (2014), 676–681.
34. 34 Carlson, KR, Pomerantz, SC, Li, J, Vafa, O, Naso, M, Strohl, W, et al. Secretion of Fc-amidated peptide fusion proteins by Chinese hamster ovary cells. BMC Biotechnol, 15, 2015, 61.
35. 35 Baselga, J, The EGFR as a target for anticancer therapy–focus on cetuximab. Eur J Cancer 37 (suppl. 4) (2001), S16–S22.
36. 36 Hynes, NE, Lane, HA, ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005), 341–354.
37. 37 Vivier, E, Raulet, DH, Moretta, A, Caligiuri, MA, Zitvogel, L, Lanier, LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science 331 (2011), 44–49.
38. 38 Li, Z, Zhao, R, Wu, X, Sun, Y, Yao, M, Li, J, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 19 (2005), 1978–1985.
39. 39 DeFazio-Eli, L, Strommen, K, Dao-Pick, T, Parry, G, Goodman, L, Winslow, J, Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res, 13, 2011, R44.
40. 40 Tracey, D, Klareskog, L, Sasso, EH, Salfeld, JG, Tak, PP, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117 (2008), 244–279.
41. 41 Klareskog, L, van der Heijde, D, de Jager, JP, Gough, A, Kalden, J, Malaise, M, et al., TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004), 675–681.
42. 42 Molineux, G, Newland, A, Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 150 (2010), 9–20.
43. 43 Herbst, RS, Hong, D, Chap, L, Kurzrock, R, Jackson, E, Silverman, JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27 (2009), 3557–3565.
44. 44 Karlan, BY, Oza, AM, Richardson, GE, Provencher, DM, Hansen, VL, Buck, M, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30 (2012), 362–371.
45. 45 Mukohara, T, Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 102 (2011), 1–8.
46. 46 Keizer, RJ, Huitema, AD, Schellens, JH, Beijnen, JH, Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49 (2010), 493–507.
47. 47 Lazar, GA, Dang, W, Karki, S, Vafa, O, Peng, JS, Hyun, L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103 (2006), 4005–4010.
48. 48 Kubota, T, Niwa, R, Satoh, M, Akinaga, S, Shitara, K, Hanai, N, Engineered therapeutic antibodies with improved effector functions. Cancer Sci 100 (2009), 1566–1572.
49. 49 Herter, S, Birk, MC, Klein, C, Gerdes, C, Umana, P, Bacac, M, Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 192 (2014), 2252–2260.
50. 50 Niwa, R, Shoji-Hosaka, E, Sakurada, M, Shinkawa, T, Uchida, K, Nakamura, K, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64 (2004), 2127–2133.
51. 51 Sioud, M, Mobergslien, A, Boudabous, A, Fløisand, Y, Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol 71 (2010), 267–274.
52. 52 Sioud, M, Skorstad, G, Mobergslien, A, Sæbøe-Larssen, S, A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells. FASEB J 27 (2013), 3272–3283.
53. 53 Bator, JM, Reading, CL, Measurement of antibody affinity for cell surface antigens using an enzyme-linked immunosorbent assay. J Immunol Methods 125 (1989), 167–176.